World Heart Fed, Daiichi Sankyo and Lilly partner on CV health

The World Heart Federation, Japan's Daiichi Sankyo and US drug major Eli Lilly have partnered to improve cardiovascular health internationally.  The organizations made the announcement at the 58th Annual Scientific  Session of the American College of Cardiology, held recently in Orlando,  Florida.

An estimated 17.5 million people died from cardiovascular disease in  2005, representing some 30% of all global deaths, making it a  significant public health concern. Through this collaboration, Daiichi  Sankyo and Lilly will reinforce the World Heart Federation's efforts  addressing the challenges that result from a cardiac event, such as a  heart attack or stent placement. In particular, the organizations will  work together in emphasizing the importance of a heart-healthy lifestyle  and adherence to medications for acute coronary syndrome patients.

"We find that people who have experienced a cardiac event often struggle  to cope with the physical and emotional impact," said Pekka Puska,  president of the World Heart Federation, adding: "this collaboration  will support patients in making the lifestyle changes that are  critical during the recovery process and beyond."